Skip to main content


Developing remyelinating therapies for the unmet need for a neuroprotective therapy for Multiple Sclerosis.
Learn More

Pheno Therapeutics is a new biotechnology company founded by the University of Edinburgh and Advent Life Sciences that builds on the ground breaking research of Profs Siddharthan Chandran and Neil Carragher, world class experts in multiple sclerosis and stem cell biology, and phenotypic screening, respectively.

Developing ground

breaking research

Based in Edinburgh and positioned to deploy the University’s world-leading expertise in phenotypic screening, stem cell technology and myelin biology, we aim to discover and develop small molecule therapeutics that promote remyelination for the treatment of multiple sclerosis.

Pheno Therapeutics aims to identify remyelinating agents: novel drugs that enhance the repair of damaged myelin sheaths in MS patients.